

## **Product datasheet for TL313958V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### **CFTR Human shRNA Lentiviral Particle (Locus ID 1080)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** CFTR Human shRNA Lentiviral Particle (Locus ID 1080)

Locus ID: 1080

Synonyms: ABC35; ABCC7; CF; CFTR/MRP; dJ760C5.1; MRP7; TNR-CFTR

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** CFTR - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 000492, NM 000492.1, NM 000492.2, NM 000492.3, BC143713, BC156254, NM 000492.4

UniProt ID: P13569

Summary: This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The

encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been

identified in the human genome. [provided by RefSeq, Aug 2017]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).